Widecells restructures board in line with growth plans

In a plan to minimise costs, refocus their strategy and target revenue growth, Stem treatment insurance provider Widecells is restructuring their board.

In line with the restructure, Chief Financial Officer David Bridgland has stepped down and will be replaced by a non-board financial controller at the end of the year. Professor Hollands has also stepped down from his board position but will remain in his role as director of the company’s storage and research division and chief scientific officer. Peter Presland, the company chairman will take on all additional duties, freeing up chief executive Joao Andrade to focus his attention on sales and business development.